InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

PROKIDNEY CORP.

PROK Clue Score13
United States Fiscal year ends December CIK 0001850270
$1.74 +4.82% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.74 −58.12% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Jul 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−27.0Net income−26.7Fiscal year 2021Operating income−55.1Net income−55.1Fiscal year 2022Revenue0.0Operating income−153.0Net income−148.1EPS, diluted−0.23Fiscal year 2023Revenue0.0Operating income−151.5Net income−35.5Fiscal year 2024Revenue0.1Operating income−183.7Net income−61.2Fiscal year 2025Revenue0.9 +1,075.0%Operating income−165.0Net income−69.0
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 0.0 0.0 0.1 0.9
Growth +1,075.0%
Operating income −27.0 −55.1 −153.0 −151.5 −183.7 −165.0
Net income −26.7 −55.1 −148.1 −35.5 −61.2 −69.0
Growth
EPS, diluted n/a n/a −0.23 n/a n/a n/a
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−241,678.9%Net margin−80,507.9%Free cash flow margin−205,078.9%Fiscal year 2025Operating margin−18,477.8%Net margin−7,725.2%Free cash flow margin−15,152.6%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −241,678.9% −18,477.8%
Net margin n/a n/a n/a n/a −80,507.9% −7,725.2%
Free cash flow margin n/a n/a n/a n/a −205,078.9% −15,152.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−25.2Capital expenditure−5.5Free cash flow−30.6Fiscal year 2021Operating cash flow−50.3Capital expenditure−5.2Free cash flow−55.5Buybacks0.0Fiscal year 2022Operating cash flow−77.1Capital expenditure−1.8Free cash flow−78.9Buybacks0.0Fiscal year 2023Operating cash flow−90.1Capital expenditure−34.2Free cash flow−124.3Buybacks−9.5Fiscal year 2024Operating cash flow−126.4Capital expenditure−29.5Free cash flow−155.9Buybacks0.0Fiscal year 2025Operating cash flow−120.1Capital expenditure−15.2Free cash flow−135.3Buybacks0.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −25.2 −50.3 −77.1 −90.1 −126.4 −120.1
Capital expenditure −5.5 −5.2 −1.8 −34.2 −29.5 −15.2
Free cash flow −30.6 −55.5 −78.9 −124.3 −155.9 −135.3
Growth
Buybacks n/a 0.0 0.0 −9.5 0.0 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash4.6Shareholders’ equity9.9Fiscal year 2021Cash20.6Shareholders’ equity26.9Fiscal year 2022Cash490.3Shareholders’ equity−1,096.6Fiscal year 2023Cash60.6Shareholders’ equity−1,103.4Fiscal year 2024Cash99.1Shareholders’ equity−995.0Fiscal year 2025Cash108.5Shareholders’ equity−1,011.2
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 4.6 20.6 490.3 60.6 99.1 108.5
Shareholders’ equity 9.9 26.9 −1,096.6 −1,103.4 −995.0 −1,011.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
4.6 20.6 490.3 60.6 99.1 108.5
n/a 11.4 10.7 42.1 42.2 51.2
n/a 40.3 518.0 420.6 441.1 335.6
Growth +1,185.4% −18.8% +4.9% −23.9%
Liabilities
n/a 13.4 13.1 29.2 39.4 34.8
Equity
n/a −161.5 −1,104.1 −1,139.7 −1,200.8 −1,269.8
9.9 26.9 −1,096.6 −1,103.4 −995.0 −1,011.2
Growth +172.9% −4,174.1%